Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of YHI-1003 (perifosine) monotherapy in relapsed or refractory neuroblastoma
jRCT2080222084Phase 1
- Sponsor
- Yakult Honsha
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of perifosine in neuroblastoma, sponsored by Yakult Honsha.
02
Drugs
perifosine
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on jRCT2080222084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222084.